3,5-Dibromosalicylaldehyde is a synthetic organic compound that has found use as a precursor in the preparation of various organic molecules. Its synthesis typically involves bromination of salicylaldehyde with bromine in the presence of a suitable catalyst. Research has explored its potential applications in diverse fields including pharmaceutical chemistry and material science. It has been investigated for its ability to form complexes with metal ions, which can be used for various purposes. Additionally, it serves as a building block for the synthesis of other bioactive compounds. Its importance stems from its versatile reactivity and ability to be incorporated into various synthetic pathways.'
```
3,5-dibromosalicylaldehyde: structure in Merck Index, 9th ed, #2995 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 7024 |
| CHEMBL ID | 229251 |
| SCHEMBL ID | 2120180 |
| MeSH ID | M0102332 |
| Synonym |
|---|
| AC-15254 |
| dalyde |
| benzaldehyde,5-dibromo-2-hydroxy- |
| 2-hydroxy-3,5-dibromobenzaldehyde |
| 90-59-5 |
| 3,5-dibromosalicylaldehyde |
| 3,5-dibromo-2-hydroxybenzaldehyde |
| 3,5-dibromosalicylaldeyde |
| nsc6221 |
| salicylaldehyde,5-dibromo- |
| nsc-6221 |
| inchi=1/c7h4br2o2/c8-5-1-4(3-10)7(11)6(9)2-5/h1-3,11 |
| nsc 6221 |
| benzaldehyde, 3,5-dibromo-2-hydroxy- |
| brn 1424739 |
| einecs 202-003-4 |
| 3,5-dibromosalicylaldehyde, 98% |
| STK198699 |
| D0188 |
| salicylaldehyde, 3,5-dibromo- |
| CHEMBL229251 |
| AKOS000268598 |
| A843591 |
| 2-[4-(dipropylsulfamoyl)benzoyl]oxybenzoic acid;3,5-dibromosalicylaldehyde |
| SCHEMBL2120180 |
| 7a260pbi3a , |
| unii-7a260pbi3a |
| 3-08-00-00188 (beilstein handbook reference) |
| FT-0614520 |
| BBL023734 |
| 3,5-dibromo-salicylaldehyde |
| 3,5-dibromo-2-hydroxybenzaldehyd |
| bdbm111000 |
| us8614253, .3-31 |
| 3,5-dibromosalicylaldehyde [mi] |
| mfcd00003318 |
| DTXSID1021796 |
| J-511255 |
| sr-01000883702 |
| SR-01000883702-1 |
| dembrexine hydrochloride monohydrate imp. c (ep); dembrexine imp. c (ep); 3,5-dibromo-2-hydroxybenzaldehyde; dembrexine hydrochloride monohydrate impurity c; dembrexine impurity c |
| BCP06387 |
| SY036779 |
| F15422 |
| F0910-0109 |
| 4,6-dibromo-2-formylphenol; dalyde; nsc 6221 |
| EN300-18188 |
| 9P-929 |
| AMY31488 |
| Q27266799 |
| CS-0013288 |
| Z57313905 |
| PD139179 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0453 | 2.2860 | 9.9390 | AID1140864 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nuclear inner membrane | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| cytoplasm | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| mitochondrion | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| endoplasmic reticulum | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| Ire1 complex | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| AIP1-IRE1 complex | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| IRE1-TRAF2-ASK1 complex | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| IRE1-RACK1-PP2A complex | Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID288818 | Cytotoxicity against BAEC after 2 days by MTT assay | 2007 | Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15 | Antiangiogenic versus cytotoxic activity in analogues of aeroplysinin-1. |
| AID288819 | Effect on tube formation of BAEC assessed as sprouting inhibition after 48 hrs | 2007 | Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15 | Antiangiogenic versus cytotoxic activity in analogues of aeroplysinin-1. |
| AID1140864 | Inhibition of human recombinant puritin-His-tagged IRE-1 RNase expressed in SF21 cells using XBP-1 RNA stem loop as substrate incubated for 30 mins prior to substrate addition measured after 2 hrs by FRET-suppression assay | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10 | Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. |
| AID288820 | Ratio of MIC for BAEC sprouting to IC50 for BAEC | 2007 | Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15 | Antiangiogenic versus cytotoxic activity in analogues of aeroplysinin-1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.12) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||